Diseases & Longevity · File 07

Long COVID. The syndrome conventional care fails to fully measure.

Between 10% and 30% of adults infected with SARS-CoV-2 develop persistent symptoms at three or more months — fatigue, brain fog, exercise intolerance, postural tachycardia, dysautonomia. It is a multisystem syndrome with measurable biology (microclots, viral persistence, autoimmunity, inflammaging) — and the conventional consultation is slow to address it because it doesn't fit any classical specialty.

Why Long COVID is not a diagnosis of exclusion

Long COVID is the first systemic post-viral syndrome studied in real time with quantifiable biomarkers. The review by Davis et al. (Nature Reviews Microbiology 2023) synthesized four central mechanisms: viral tissue persistence, microcoagulation with fibrin deposition, de novo autoimmunity, and mitochondrial dysfunction. That turns Long COVID into a condition with measurable biology, not a wastebasket.

The UK cohort by Subramanian et al. (Nature Medicine 2022, n=486,149 confirmed COVID vs 1.94 million control) quantified 62 symptoms significantly more frequent in infected patients at 12 weeks — from anosmia and dyspnea to hair loss, reduced libido, and ejaculatory disorder. Distribution by gender, age, and comorbidity is heterogeneous, demanding a clinical phenotype approach instead of a single protocol.

Long COVID has biology — microclots, viral persistence, autoimmunity, mitochondria. The question is not whether it exists, but what phenotype each patient has.
Subramanian · Nature Medicine · 2022

The global weight, in numbers

The Long COVID burden was counted from global cohorts — UK Biobank, ZOE Study, hospital vs outpatient data, and post-pandemic meta-analyses. These are the evidence points that support the clinical picture.

  • Infected adults with symptoms at 3+ months

    10–30%

    Range consolidated in Davis 2023 Nature Reviews Microbiology review — varies by clinical definition, initial severity, and prior vaccination.
    — Davis et al., Nat Rev Microbiol 2023

  • Symptoms significantly more frequent at 12 weeks

    62

    Subramanian 2022 Nature Medicine UK cohort, n=486,149 vs 1.94M control. From fatigue and dyspnea to anosmia, alopecia, and sexual dysfunction.
    — Subramanian et al., Nat Med 2022

  • Global estimate of people with Long COVID

    65M+

    Conservative estimate at 2023 — based on confirmed infections + average 10% persistence rate. Real figure could be higher considering unconfirmed infections.
    — Davis et al., Nat Rev Microbiol 2023

  • Long COVID patients meeting ME/CFS criteria

    60%

    Subgroup with post-exertional malaise (PEM) that phenotypically overlaps with myalgic encephalomyelitis / chronic fatigue syndrome — shared pathophysiology (mitochondria, autoimmunity) opens common therapeutic pathways.
    — Davis et al., Nat Rev Microbiol 2023

Chap. 03 · Work disability · 6 months

Impact on quality of life and work trajectory

Beyond mortality — where Long COVID truly disrupts is functional and work capacity. Disability, return-to-work, and economic burden data are consistent with other major chronic systemic illnesses.

  • Severely reduced work capacity

    Davis Nat Rev Microbiol 2023

    Up to 22% of Long COVID patients report inability to work full-time at 6 months (US, UK, EU cohorts). The PEM subgroup has even lower return-to-work rates.

  • Brain fog and executive impairment

    Hampshire Nat Med 2024

    Cognitive deficits in Long COVID are measurable: attention, processing speed, working memory. Equivalent to 20+ years of aging in UK cohorts (Hampshire 2024 Nat Med).

  • POTS and persistent dysautonomia

    Davis Nat Rev Microbiol 2023

    Up to 30% of Long COVID patients meet POTS criteria (postural orthostatic tachycardia syndrome), a condition that significantly reduces SF-36 and aerobic functional capacity.

  • Sustained increase in cardiovascular risk

    Xie Nat Med 2022

    Xie 2022 Nature Medicine cohort (n=153,760 post-COVID vs 5.6M control): sustained increase in MI, stroke, HF, arrhythmia, and thromboembolism risk at 12 months — independent of initial severity.

Why a longevity protocol addresses Long COVID

Long COVID is the first disease of the post-pandemic era where the conventional system openly acknowledges its limits — no classical specialty manages it, no approved treatment exists, biomarkers are still under research. That is why many patients end up navigating between cardiology, neurology, pulmonology, infectious diseases, and rheumatology without anyone giving them an integrated view.

Longevity medicine does not replace the specialist nor promises a single cure. What it does is what the fragmented model does not: it measures the shared biological axes of Long COVID (microcoagulation, inflammaging, emerging autoimmunity, autonomic function, mitochondria) and designs an individualized intervention plan under medical judgment. Emerging plasma exchange evidence in immunoglobulin apheresis (Achleitner 2023 Molecular Psychiatry) is one of several tools we evaluate case by case.

Long COVID is the disease where the conventional model's fracture is most visible. Measure shared axes, integrate — that is what is missing.
How we measure it

How it is evaluated at Wellness Care

Three complementary layers under a longevity medicine protocol — none replaces specialized medical management when clinically indicated.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Long COVID — category

Evidence of plasma exchange in Long COVID — Achleitner et al. Molecular Psychiatry 2023, post-viral fatigue mechanisms.

Explore →

Therapeutic plasma exchange

Spectra Optia, Buck Institute evidence (Fuentealba 2025), inflammaging modulation, and peripheral clearance.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications framing Long COVID in the longevity conversation — pathophysiology synthesis, global cohorts, and emerging plasma exchange evidence.

«Long COVID es una condición multisistémica con al menos cuatro mecanismos centrales: persistencia viral, microcoagulación, autoinmunidad y disfunción mitocondrial — todos medibles, todos con vías terapéuticas en investigación.»

Revisión fisiopatológica integral
Davis et al., Nat Rev Microbiol 2023
Revisión fisiopatológica integral

«62 síntomas fueron significativamente más frecuentes a 12 semanas en adultos infectados vs control — desde anosmia y disnea hasta caída del cabello y disfunción sexual.»

Cohorte UK n=486,149 post-COVID
Subramanian et al., Nat Med 2022
Cohorte UK n=486,149 post-COVID

«La aféresis de inmunoglobulinas en pacientes con Long COVID con autoanticuerpos detectables mostró mejoría sintomática significativa en un subgrupo seleccionado — abriendo una vía terapéutica para fenotipos autoinmunes.»

Evidencia emergente de aféresis en Long COVID
Achleitner et al., Mol Psychiatry 2023
Evidencia emergente de aféresis en Long COVID

Frequently asked questions about Long COVID

The most recurrent questions about Long COVID, identifiable biological phenotypes, and how Wellness Care addresses the condition without False promises but with the biology that can be measured.

01

How long must symptoms last to call it Long COVID?

NICE 2022 guidelines and WHO define Long COVID as symptoms that persist or appear after the acute phase of SARS-CoV-2 and last 12 weeks or more, with no other explanation.

Operational definitions:

· 4 weeks — continuous symptoms
· 12 weeks — established syndrome
· ICD-10 code: U09.9

02

Is Long COVID just fatigue, or more symptoms?

It is a multisystem syndrome. The Subramanian 2022 cohort identified 62 symptoms significantly more frequent in infected at 12 weeks:

· Fatigue / brain fog
· Dyspnea / palpitations
· Postural tachycardia
· Persistent anosmia / ageusia
· Alopecia
· Exercise intolerance
· Joint pain
· Sleep disturbances
· Anxiety / post-viral depression
· Sexual dysfunction

Presentation is heterogeneous and requires a phenotype approach.

03

Does prior vaccination reduce Long COVID risk?

Yes, with moderate effect.

Multiple post-pandemic meta-analyses showed that pre-infection vaccination reduces Long COVID risk by approximately 15-40% (heterogeneous range by variant, schedule, age, and comorbidities).

Post-infection vaccination also shows symptomatic improvement in a fraction of patients, though evidence is more mixed.

04

Which biomarkers are measured in Long COVID?

In longevity medicine we evaluate:

· Inflammatory profile — hsCRP, IL-6, ferritin, fibrinogen
· Microcoagulation — D-dimer, thrombin-antithrombin complexes
· Emerging autoimmunity — GPCR autoantibodies, ANA, anti-receptor
· Autonomic function — HRV, tilt table in POTS suspicion
· Mitochondrial fatigue — lactate, CoQ10, carnitine
· Symptom burden — PEM, brain fog scales

No single biomarker defines Long COVID — pattern guides phenotype.

05

Does plasma exchange (TPE) help in Long COVID?

The most solid evidence to date is Achleitner et al. (Molecular Psychiatry 2023), which showed significant symptomatic improvement in Long COVID patients with detectable autoantibodies after immunoglobulin apheresis.

It is preliminary evidence — not applicable to every Long COVID patient.

At Wellness Care, TPE is evaluated case by case, under individual medical judgment, within applicable INVIMA framework, and only in phenotypes where evidence and biomarkers justify it.

06

When should I consult for suspected Long COVID?

A structured assessment is worthwhile if you have 3 months or more with:

· Persistent fatigue
· Brain fog
· Palpitations on standing
· Post-COVID exercise intolerance
· Unexplained joint pain
· Sleep disturbance that does not remit

Especially if you were previously active and functional.

A confirmed acute-phase COVID test is not required: the clinical definition accepts reasonable suspicion of prior infection.

The question is not whether it exists

The honest clinical question is not whether Long COVID exists — biology is documented. It is what phenotype each patient has and what can be measured and modulated today.

Measure shared biological axes, coordinate with specialties when indicated, integrate tools with emerging evidence under individual medical judgment — that is what's missing in the fragmented model.

Months without recovering?

Book a comprehensive Long COVID assessment

We evaluate immuno-inflammatory profile, microcoagulation markers, autonomic function (HRV), exercise tolerance, and symptom burden. If you have more than 3 months of fatigue, brain fog, palpitations on standing, or post-COVID exercise intolerance — this is what we do.

Book Long COVID assessment